MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting α-synuclein expression in MPTP-induced Parkinson's disease mouse

Biomedicine and Pharmacotherapy

Volumn 74, Issue , 2015, Pages 252-256

  Wang, Zhao Hui ^a   Zhang, Jian Lei ^a   Duan, Yan Li ^b   Zhang, Qi Shun ^a   Li, Guo Fei ^a   Zheng, Dong Lin ^a  

^a HENAN UNIVERSITY   (China)

^b Kaifeng Eye Hospital   (China)

Author keywords

MiR 214; Parkinson's disease; Resveratrol; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; MESSENGER RNA; MICRORNA 214; RESVERATROL; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; MICRORNA; MIRN214 MICRORNA, MOUSE; NEUROPROTECTIVE AGENT; STILBENE DERIVATIVE;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MESENCEPHALON; MOUSE; MPTP-INDUCED PARKINSONISM; NEUROBLASTOMA CELL LINE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEUROBLASTOMA; PARKINSONIAN DISORDERS; TUMOR CELL LINE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ALPHA-SYNUCLEIN; ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; RNA, MESSENGER; STILBENES; UP-REGULATION;

EID: 84940876770     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.08.025     Document Type: Article

References (36)

1. Alves G., et al. Epidemiology of Parkinson's disease. J. Neurol. 2008, 255(Suppl 5):18-32.
2. De Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5(6):525-535.
3. Spillantini M.G., et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(11):6469-6473.
4. Singleton A.B., et al. α-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302(5646):841.
5. Olanow C.W., Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?. Mov Disord. 2013, 28(1):31-40.
6. He S., Yan X. From resveratrol to its derivatives: new sources of natural antioxidant. Curr. Med. Chem. 2013, 20(8):1005-1017.
7. Csiszar A. Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Ann. N. Y. Acad. Sci. 2011, 1215:117-122.
8. Conte E., et al. Anti-inflammatory and antifibrotic effects of resveratrol in the lung. Histol. Histopathol. 2014, 30(5):523-529.
9. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5(6):493-506.
10. Li H., Xia N., Forstermann U. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 2012, 26(2):102-110.
11. Albani D., et al. Neuroprotective properties of resveratrol in different neurodegenerative disorders. Biofactors 2010, 36(5):370-376.
12. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136(2):215-233.
13. Zimmerman A.L., Wu S. MicroRNAs cancer and cancer stem cells. Cancer Lett. 2011, 300(1):10-19.
14. Ikeda S., et al. Altered microRNA expression in human heart disease. Physiol. Genomics 2007, 31(3):367-373.
15. Hebert S.S., De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 2009, 32(4):199-206.
16. Nelson P.T., Wang W.X., Rajeev B.W. MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol. 2008, 18(1):130-138.
17. Liu J., et al. Role of miRNAs in neuronal differentiation from human embryonic stem cell-dericed neural stem cells. Stem Cell Rev. 2012, 8(4):1129-1137.
18. Kabaria S., et al. Inhibition of miR-34b and miR-34c enhances alpha-synuclein expression in Parkinson's disease. FEBS Lett. 2015, 589(3):319-325.
19. Chang T.C., Mendell J.T. microRNAs in vertebrate physiology and human disease. Annu. Rev. Genomics Hum. Genet. 2007, 8:215-239.
20. Wang G., et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of α-synuclein. Am. J. Hum. Genet. 2008, 82(2):283-289.
21. De Mena L., et al. Analysis of the Micro-RNA-133 and PITX3 genes in Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153(6):1234-1239.
22. Villar-Menéndez I., et al. Increased striatal adenosine A 2A receptor levels is an early event in Parkinson's disease-related pathology and it is potentially regulated by miR-34b. Neurobiol. Dis. 2014, 69:206-214.
23. Wang Q., et al. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 2002, 958(2):439-447.
24. Sun A.Y., et al. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol. Neurobiol. 2010, 41(2-3):375-383.
25. Blanchet J., et al. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(5):1243-1250.
26. Lofrumento D.D., et al. Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immun. 2014, 20(3):249-260.
27. Stefanis L. α-Synuclein in Parkinson's disease. CSH Perspect Med. 2012, 2(2):a009399.
28. Albani D., et al. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J. Neurochem. 2009, 110(5):1445-1456.
29. Wu Y.et al. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neuro-Signals 2011, 19(3):163.
30. Yang H., et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68(2):425-433.
31. Zhang X.J., et al. Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J. Hematol. Oncol. 2010, 3:46. 46.
32. Wang X., et al. miR-214 targets ATF4 to inhibit bone formation. Nat. Med. 2013, 19(1):93-100.
33. Van Balkom B.W., et al. Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells. Blood 2013, 121(19):3997-4006.
34. Roshan R., et al. MicroRNAs: novel therapeutic targets in neurodegenerative diseases. Drug Discov. Today 2009, 14(23-24):1123-1129.
35. Chen H., et al. miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neurite outgrowth in vitro. Biochem. Biophys. Res. Commun. 2010, 394(4):921-927.
36. Doxakis E. Post-transcriptional regulation of α-synuclein expression by mir-7 and mir-153. J. Biol. Chem. 2010, 285(17):12726-12734.